一、担保情况概述 证券代码：002693 证券简称：*ST双成 公告编号：2025-045 海南双成药业股份有限公司 关于为控股子公司提供担保暨关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别风险提示： 公司本次提供担保的对象为合并报表范围内的控股子公司，其最近一期经审 计的资产负债率超过 70%，但其经营状况良好，公司能够全面掌控其运行，担保 风险可控。特此提醒投资者充分关注担保风险。 海南双成药业股份有限公司（以下简称"公司"）控股子公司宁波双成药业 有限公司（以下简称"宁波双成"）因日常经营需要，拟向中国建设银行股份有 限公司宁波杭州湾新区支行（以下简称"建设银行"）申请 4,000 万元借款，借 款期限至 2028 年 7 月 31 日。公司和公司控股股东海南双成投资有限公司（以下 简称"双成投资"）拟为宁波双成向建设银行借款分别提供连带责任担保，担保 期限为主合同下的债务履行期届满之日起三年。 双成投资为公司控股股东，同时持有宁波双成 48.81%的股份。根据《深圳 证券交易所股票上市规则》等相关规定，本次对外提供担保构成关联交易 ...

Core Viewpoint - The first half of 2025 financial reports from A-share listed companies reveal significant profit increases, with several companies projecting profit growth exceeding tenfold compared to the previous year [1][5]. Group 1: Company Performance - Zhongyan Chemical's 2025 half-year report shows a revenue of 5.998 billion yuan, a decrease of 5.76% year-on-year, with a net profit of 52.7155 million yuan, down 88.04% year-on-year [3][4]. - The decline in Zhongyan Chemical's revenue is attributed to intensified market competition and significant price drops in key products like soda ash and PVC, despite a 38.82% increase in sales volume [3][4]. - Huahong Technology expects a net profit of 70 million to 85 million yuan for the first half of 2025, representing a year-on-year increase of 3047.48% to 3721.94%, driven by improved prices of rare earth raw materials [6][7]. - Wannianqing anticipates a net profit of 31 million to 45 million yuan, reflecting a year-on-year growth of 1954.07% to 2881.71%, supported by recovering demand in the cement industry and cost reduction efforts [6][7]. - Other companies like Yatai Pharmaceutical and Aerospace Science and Technology also project substantial profit increases, with expected growth rates of 1726.42% to 1909.06% and 1628.83% to 2315.27%, respectively [7]. Group 2: Market Trends - The overall trend indicates a recovery in certain sectors, such as the cement industry, due to reduced declines in real estate investment and infrastructure spending [7]. - The chemical industry is experiencing price fluctuations, with some products seeing significant price drops due to weakened downstream demand, while others like caustic soda have increased prices due to demand pull [4].

Group 1 - The core project is the flexible production line renovation project for synthetic biology at Zhejiang Haizheng Pharmaceutical Co., Ltd., with a total investment of 171.06 million yuan, including 5.1 million yuan for environmental protection [2][4]. - The project aims to produce 72,000 tons of 60% liquid glucose, 93,816 tons of 30% liquid glucose, 1,500 tons of yeast, and various other products annually, including 2,000 tons of HS31101 sulfate and 1,000 tons of HS31101 hydrochloride [2][3]. - The project will utilize existing production lines in the Y108, Y109, Y110, Y112, and Y27 workshops at the Yantou plant [2][3]. Group 2 - The fourth Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held in Ningbo, Zhejiang, from August 20 to 22, focusing on five key areas: AI + biological manufacturing, green chemicals and new materials, future food, future agriculture, and beauty raw materials [5][6]. - The conference aims to explore the development trends of the bio-manufacturing industry during the 14th Five-Year Plan and discuss innovative technologies and products that will sustain the industry [5].

Core Viewpoint - Dezheng Health (000813) expects a net profit loss of 25 million to 50 million yuan in the first half of 2025, compared to a profit of 10.15 million yuan in the same period last year, representing a year-on-year decline of 346.24% to 592.48% [1] Financial Summary - The projected net profit loss for the first half of 2025 is between 25 million and 50 million yuan [1] - The profit for the same period last year was 10.15 million yuan [1] - The year-on-year decline in net profit is estimated to be between 346.24% and 592.48% [1]

Group 1 - Hubei Changjiang No.1 Health Industry Investment Partnership has been established with a capital contribution of 3.401 billion RMB, primarily funded by Hubei Changjiang Industrial Investment Fund Co., Ltd. and Hubei Changjiang New Kinetic Energy Private Fund Management Co., Ltd. [1] - The fund aims to accelerate the development of the biopharmaceutical and health industry in Hubei, which is a key strategic pillar industry for the province, projected to reach a trillion-level scale [1][3]. - The establishment of the fund is expected to effectively promote the construction of biopharmaceutical industrial parks and project introductions [1]. Group 2 - Guangji Pharmaceutical, as the only provincial-level listed pharmaceutical company in Hubei, is a significant subsidiary of Changjiang Industrial Group, producing various vitamin products and serving as a major supplier of Vitamin B2 globally [2]. - The fund will provide strong capital support for Guangji Pharmaceutical in terms of industrial collaboration, project implementation, mergers, and development [2]. - The fund will also establish an expert committee to provide intellectual support for project advancement, enhancing the scientific and forward-looking aspects of industry development [2]. Group 3 - Changjiang Industrial Group was established in January 2022, with a registered capital of 33.6 billion RMB and total assets of 250.9 billion RMB, managing over 700 billion RMB in funds [3]. - The health industry in Hubei has surpassed 850 billion RMB in scale, accounting for 15% of the province's GDP, with expectations to exceed 950 billion RMB by 2025, reflecting a compound annual growth rate of 12%-15% [3]. - The "14th Five-Year Plan" for the development of the health industry in Hubei includes the establishment of a 10 billion RMB guiding fund to support sectors such as biopharmaceuticals and medical devices [3]. Group 4 - By the end of 2024, the number of high-tech enterprises in Hubei's health sector is expected to exceed 1,500, marking a 65% increase since 2020 [4]. - In the chemical pharmaceutical sector, companies like Renfu Pharmaceutical and Yuanda Pharmaceutical lead in specific markets such as anesthetics and eye drops [4]. - Wuhan Optics Valley Biomedicine City has over 400 biopharmaceutical companies, forming a regional cluster advantage in areas like genetic engineering and vaccine development [4].

金十图示：2025年07月14日（周一）富时中国A50指数成分股今日收盘行情一览：电力、煤炭、石油板块全天表现强劲，银行、 酿酒板块涨跌互现 +0.04(+0.71%) +0.06(+0.50%) +0.16(+1.88%) 光大银行 2593.86亿市值 8.75亿成交额 4.39 +0.05(+1.15%) 保险 中国平安 中国太保 中国人保 0 3781.15亿市值 3684.59亿市值 10483.63亿市值 9.71亿成交额 25.99亿成交额 8.16亿成交额 38.30 57.57 8.55 -0.16(-0.42%) -0.14(-0.24%) +0.07(+0.83%) 酿酒行业 贵州茅台 山西汾酒 五粮液 17883.23亿市值 2171.17亿市值 4867.92亿市值 39.62亿成交额 27.34亿成交额 9.45亿成交额 1423.60 177.97 125.41 -3.40(-0.24%) +0.48(+0.27%) +1.11(+0.89%) 半导体 北方华创 寒武纪-U 海光信息 HYGON 2339.37亿市值 2363.93亿市值 3163.42亿市值 12.62亿成交额 ...

Group 1: Market Overview - The FTSE China A50 Index components showed a strong performance in the banking sector, with significant gains across various industries including power, coal, and oil, while the securities and consumer electronics sectors experienced declines [1][6]. Group 2: Sector Performance - The banking sector saw a rise in stock prices, with notable increases in major banks such as China Pacific Insurance and China Ping An, which had market capitalizations of 378.56 billion and 1,053.46 billion respectively [3]. - The power, coal, and oil sectors also performed well, with China Petroleum and China Shenhua Energy showing positive stock movements [4]. - Conversely, the securities sector, including firms like CITIC Securities, faced a decline, with a drop of 0.73% in stock price [4]. - The semiconductor industry had mixed results, with North China Innovation experiencing a decrease of 1.85%, while Cambrian Technology saw an increase of 2.35% [3][4]. Group 3: Notable Companies - Major companies in the liquor industry, such as Kweichow Moutai and Wuliangye, reported market capitalizations of 1,788.34 billion and 483.65 billion respectively, with Kweichow Moutai's stock price showing a slight decline of 0.24% [3]. - In the automotive sector, BYD's stock price increased by 0.31%, while other companies like SAIC Motor faced a decline [4]. - The technology sector, represented by companies like Industrial Fulian and Luxshare Precision, showed a downward trend, with stock prices decreasing by 0.69% and 0.65% respectively [4].

Core Viewpoint - Chengyi Pharmaceutical (603811) expects a significant increase in net profit for the first half of 2025, driven by the growth in joint health drug sales and reduced losses from subsidiaries [1][2] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of between 107 million to 119 million yuan, representing a year-on-year growth of 40% to 55% [1] - The expected non-net profit is projected to be between 106 million to 113 million yuan, with a year-on-year increase of 47.4% to 57.4% [1] - Revenue from joint health drugs is expected to grow by 23.41% year-on-year, reaching 502 million yuan in 2024, with a continued growth trend into the first quarter of 2025, where revenue is expected to increase by 49.62% year-on-year to 143 million yuan [1] Group 2: Product Advantages - Chengyi Pharmaceutical is a major integrated manufacturer of glucosamine, benefiting from four key advantages: product positioning focused on elderly joint health, dual licenses for raw material and formulation production, self-sourced raw materials ensuring cost and quality, and a favorable geographic location in Wenzhou [2] - The company utilizes marine resources for its glucosamine production, aligning with government policies emphasizing the development of marine economy and biotechnology [2] Group 3: Strategic Initiatives - The company is advancing a project to build a thousand-ton capacity for high-purity EPA fish oil, which is in high demand and has received FDA approval for lowering blood lipids [3] - The infrastructure for the health industry park is complete, and the review for high-purity EPA formulations is nearing completion, which will enable a full supply chain from raw materials to health products and pharmaceuticals [3] Group 4: Employee Incentives - The company has proposed an employee stock ownership plan, aiming to raise up to approximately 48.29 million yuan, with a share price set at 5.02 yuan per share [3][4] - The plan includes performance targets for revenue and non-net profit growth over three years, with specific growth rates set for 2025, 2026, and 2027 [4] - The implementation of this plan is intended to enhance employee engagement and align interests between employees and shareholders, supporting the company's high-quality development [4]

Group 1 - The A-share market has shown strong upward momentum, with the Shanghai Composite Index breaking through the 3500-point mark and trading volume exceeding 1.7 trillion yuan [2] - The financial sector has led the market rally, supported by a surge in short-term capital chasing high-performing stocks as semi-annual earnings forecasts are released [2] - Institutions suggest that investors should shift from a trading strategy to a holding strategy in light of the market's transition from a stock-based to an incremental market [4][5] Group 2 - Positive factors for the A-share market continue to accumulate, with strong risk appetite reflected in trading behavior and capital flows [3] - The market is increasingly focusing on fundamental factors rather than external disturbances, indicating a shift in pricing dynamics [3] - The strong upward trend in the A-share market is expected to continue, with significant conditions for a major rally accumulating [3] Group 3 - The market has seen a shift from net outflows to net inflows in actively managed public funds since June, marking a reversal in the trend of capital withdrawal [4] - Different sectors, including non-ferrous metals, telecommunications, and gaming, have shown synchronized upward movement, indicating the presence of incremental capital across various funding entities [5] Group 4 - The performance of semi-annual earnings is crucial for trading strategies, with sectors like TMT (Technology, Media, and Telecommunications) expected to perform well [6] - High-growth industries such as automotive parts, automation equipment, and consumer goods are recommended for investment, alongside sectors with improving performance like precious metals and pharmaceuticals [6] - Predictions indicate that industries such as light industry, non-ferrous metals, and non-bank financials may experience high growth rates in their semi-annual earnings [6]

Core Viewpoint - The implementation of the 2025 employee stock ownership plan by Zhejiang Chengyi Pharmaceutical Co., Ltd. is expected to enhance the alignment of interests between employees and shareholders, improve employee motivation, and contribute to the company's long-term sustainable development [1][2]. Summary by Sections Employee Stock Ownership Plan - The 2025 employee stock ownership plan aims to establish and improve the mechanism for sharing interests between employees and shareholders, thereby enhancing the company's competitiveness and cohesion among employees [1]. - The draft of the 2025 employee stock ownership plan complies with relevant regulations and does not harm the interests of the company or all shareholders [1]. - Participation in the employee stock ownership plan is based on voluntary compliance, with no forced participation or distribution among employees [1].